Tagged Articles

medication 93 articles

Paula Deen and sons team up with drug maker to push recipes for diabetics

Paula Deen and her two sons, Bobby and Jamie, are teaming up with drug maker Novo Nordisk for a national initiative aimed at helping diabetics like Paula overcome common challenges associated with type 2 diabetes management. The campaign, called Diabetes in a New Light, features recipes for lighter versions of some of Paula’s favorite summertime recipes. Earlier this year, Paula announced she had been diagnosed with type 2 diabetes three years prior. She chose to come clean about her disease after signing a lucrative deal with Novo Nordisk to promote its type 2 diabetes drug Victoza. The celebrity chef’s announcement ... Read More

Paula Deen’s deal with diabetes drug among ‘Most Questionable’ celebrity chef deals

Huffington Post has named Paula Deen’s deal to promote a type 2 diabetes drug among “The 13 Most Questionable Deals” made by celebrity chefs. “Everyone has to make a living, even celebrity chefs. That disclaimer aside, the last few years have seem more than a few celebrity chef endorsements that raise an eyebrow or three,” the publication reported. “We hear about the most egregious ones in the press – like butter-evangelist Paula Deen’s deal with a diabetes medication that went public just after she announced her own diabetes diagnosis…” Deen’s decision to come clean about her type 2 diabetes diagnosis three ... Read More

Company apologizes for birth defects caused by drug given to pregnant women

German drug maker Gruenenthal Group is apologizing to women who took its morning sickness medication Thalidomide in the 1950s and 1960s, and to their children who suffered congenital birth defects as a result. The apology comes 50 years after the drug was pulled off the market for causing babies to be born with shortened arms and legs or with no limbs at all. “We ask that you regard our long silence as a sign of the shock that your fate caused in us,” said Harald Stock, Gruenenthal Group’s chief executive, during an unveiling of a statute in the drug company’s ... Read More

FDA approves new 4-in-1 pill to treat HIV

The Food and Drug Administration (FDA) has approved a new 4-in-1 pill to fight HIV, the virus that causes AIDS. Stribild, a once-daily medication made by Gilead Sciences, was approved to treat adults with HIV who have not previously been treated for the infection. Stribild combines two already-approved antiviral drugs, emtricitabine and tenofovir disoproxil fumarate, which are the active ingredients in the HIV treatment Truvada. The pill also includes the new drugs elvitegravir and cobicistat. Elvitegravir works by interfering with one of the enzymes HIV relies on to multiply. Cobicistat helps to lengthen the effect of elvitegravir. Clinical trials showed ... Read More

Study finds long-term Actos, Avandia use increases risk for bladder cancer

When the Food and Drug Administration (FDA) last year issued a warning that the type 2 diabetes drug Actos (pioglitazone) was shown to increase users’ risk for bladder cancer, its warning was based on limited data from the Kaiser Permanente Northern California diabetes registry, the French national health information system, and the PROspective pioglitazone Clinical Trail In macroVascular Events study. “None of the previous studies directly compared the TZDs (the class of drugs that includes Actos) with sulfonylureas (SUs), the common alternative therapy for type 2 diabetes not adequately controlled with metformin,” says Ronac Mamtani with the University of Pennsylvania. ... Read More

Type 2 diabetes drug Actos now available in generic versions

The type 2 diabetes drug Actos (pioglitazone) is now available as a lower-costing generic. Actos is marketed by Japanese drug maker Takeda Pharmaceuticals. The patent for Actos expires in 2016; however, under the terms of a 2010 legal settlement, generic versions can be marketed as early as August 17, 2012. Both Ranbaxy Laboratories and Teva Pharmaceuticals are now selling generic Actos in three different doses. Another generic drug company, Watson Pharmaceuticals, had hoped to launch a generic version of Actos this week, but the Food and Drug Administration (FDA) has yet to grant the drug final approval. Last week, Watson ... Read More

Actos may be tested as treatment for Alzheimer’s disease

The type 2 diabetes drug Actos, which was recently linked to bladder cancer, may soon be tested on people with Alzheimer’s disease to see if it can help with memory retention. Researchers at the University of Virginia Health System and Case Western Reserve University say that drugs used to keep high blood sugar in check may also help slow memory loss. With this in mind, researchers focused on the drug Actos (pioglitazone). “We believe that the drug may reduce the body’s inflammatory reaction to one of the toxic components that builds up in Alzheimer’s, called amyloid plaque,” says Dr. David ... Read More

Normal weight type 2 diabetics more likely to die from disease than overweight, obese diabetics

Normal-weight people with type 2 diabetes are twice as likely to die from the disease than overweight or obese people with type 2 diabetes, according to a new study recently published in the Journal of the American Medical Association. The study compared death rates among 2,625 type 2 diabetics aged 40 and older, and found that the death rate among normal-weight diabetics was 284.8 per 10,000 person-years compared to 152.1 per 10,000 person-years in overweight or obese diabetics. They also found that older adults and non-white participants were more likely to develop type 2 diabetes at a normal weight. Researchers ... Read More

Trials on Alzheimer’s treatment halted after disappointing results

Pfizer and Johnson & Johnson are halting the development of a drug to treat mild to moderate Alzheimer’s disease after the drug failed to show improvement over a placebo in two late-stage clinical trials. The drug, an intravenous formulation of bapineuzumab, is designed to prevent the buildup of plaque in the brain. Despite the setback, Johnson & Johnson says it is not discontinuing the development of the compound and will continue with studies on mid-stage neuroimaging with bapineuzumab delivered subcutaneously. Bapineuzumab is a monoclonal antibody intended to break up beta amyloid protein plaques, and some researchers believe the drug may be ... Read More

Pumping iron reduces men’s risk for developing type 2 diabetes

Men who pump iron are less likely to develop type 2 diabetes, according to a new study published in a recent issue of the Archives of Internal Medicine. For the study, researchers from Harvard University and the University of Southern Denmark followed 32,000 men from 1990 until 2008. They studied the role exercise and weight training had on their risk for diabetes, a condition that affects nearly 350 million people worldwide. About 2,275 people developed diabetes during the study period. After adjusting for factors such as television viewing habits, family history, smoking, and diet, researchers categorized the men into three ... Read More